HealthTech: $35M to study sleep disorders | Predicting colon cancer risk | Health data
ST. LOUIS, MO—People with REM sleep behavior disorder act out their dreams (if they’re running in a dream, they might move their legs). A team at Washington University School of Medicine in St. Louis, Mayo Clinic, and The Neuro of McGill University has received a five-year grant expected to total $35.1 million to develop biomarkers that indicate which people with the sleep disorder will go on to develop neurodegenerative diseases.
INDIANAPOLIS, IN—Researchers have created novel scoring tools for predicting actual risk of colon cancer and advanced precancerous polyps for patients at average risk for the disease. The work was led by Thomas F. Imperiale, M.D., Regenstrief Institute and U.S. Department of Veterans Affairs research scientist, and Indiana University School of Medicine professor.
KANSAS CITY, MO—Health IT company Cerner is adding to its revenue cycle management portfolio by launching Cerner RevElate, a result of their investment in advancing patient accounting capabilities and enterprise-wide technology optimization. Cerner RevElate is expected to reduce complexity by managing data and workflows that scale for large health systems.
PITTSBURGH, PA—New York-based musculoskeletal therapy provider SWORD Health has acquired Pittsburgh-based Vigilant Technologies (VIT), a workplace injury prevention company, for an undisclosed sum. VIT makes wearable tech that teaches users how to prevent soft tissue injury and pain in the workplace. VIT will stay in Pittsburgh.
- COLUMBUS, OH—Boston-based Sarepta Therapeutics Inc. has opened a research hub called the Genetic Therapies Center of Excellence in Columbus. Several of the therapies for which clinical trials will be conducted were actually invented by Louise Rodino-Klapac, Ph.D., at Nationwide Children’s Hospital.